Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer

US12227577B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Marat Alimzhanov · Wellesley, US
• Patricia Soulard · Lexington, US
• Frank Zenke · Darmstadt, DE
• Heike Dahmen · Darmstadt, DE
• Astrid Zimmermann · Konstanz, DE
• Andreas Schroeder · Heidelberg, DE
• Keyvan Tadjalli Mehr · Heidelberg, DE
• Martin Falk · Rödermark, DE

Key dates

• Filing date: Sep 26, 2019
• Grant date: Feb 18, 2025
• Expiry date: Mar 23, 2042

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 antagonist, an ATR inhibitor and a platinating agent.